Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01642004
Registration number
NCT01642004
Ethics application status
Date submitted
9/07/2012
Date registered
17/07/2012
Date last updated
28/12/2022
Titles & IDs
Public title
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
Query!
Scientific title
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Query!
Secondary ID [1]
0
0
2011-004792-36
Query!
Secondary ID [2]
0
0
CA209-017
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Squamous Cell Non-small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Nivolumab
Treatment: Drugs - Docetaxel
Experimental: Arm A: Nivolumab - Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
Experimental: Arm B: Docetaxel - Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
Other interventions: Nivolumab
Treatment: Drugs: Docetaxel
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint
Query!
Assessment method [1]
0
0
OS was defined as the time between the date of randomization and the date of death from any cause. Participants were censored at the date they were last known to be alive. Median OS time was calculated using Kaplan-Meier (KM) method. Hazard ratio (HR) and the corresponding Confidence Interval (CI) were estimated in a stratified Cox proportional hazards model for distribution of OS in each randomized arm. Interim analysis (Primary Endpoint) was planned to occur after at least 196 deaths, with the actual analysis occurring at 199 deaths.
Query!
Timepoint [1]
0
0
Randomization until 199 deaths, up to November 2014, approximately 25 months
Query!
Primary outcome [2]
0
0
Overall Survival (OS) Rate in All Randomized Participants
Query!
Assessment method [2]
0
0
The overall survival rate is the probability that a participant will be alive at 6, 12, and 18 months following randomization. Overall survival was defined as the time between the date of randomization and the date of death as a result of any cause. Survival rates were determined via Kaplan-Meier estimates.
Query!
Timepoint [2]
0
0
Randomization to 18 months post-randomization, up to June 2015
Query!
Primary outcome [3]
0
0
Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint
Query!
Assessment method [3]
0
0
The number of participants who died from any cause was reported for each arm. Interim analysis (Primary Endpoint) was planned to occur after at least 196 deaths, with the actual analysis occurring at 199 deaths.
Query!
Timepoint [3]
0
0
Randomization until 199 deaths, up to November 2014, approximately 25 months
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR) in All Randomized Participants
Query!
Assessment method [1]
0
0
ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). BOR was defined as the best investigator-assessed response designation, recorded between the date of randomization and the date of objectively documented progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or the date of subsequent anti-cancer therapy (excluding on-treatment palliative radiotherapy of non-target bone lesions or Central Nervous System (CNS) lesions), whichever occurred first. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CIs were computed using the Clopper and Pearson method.
Query!
Timepoint [1]
0
0
From the date of randomization up to the date of objectively documented progression, up to approximately 103 months
Query!
Secondary outcome [2]
0
0
Time To Response (TTR) in Months for All Confirmed Responders
Query!
Assessment method [2]
0
0
Time to Response (TTR) for participants demonstrating a response (either CR or PR) was defined as the time from the date of randomization to the date of the first confirmed response. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters.
Query!
Timepoint [2]
0
0
From the date of randomization to the date of the first confirmed response, up to approximately 12 months
Query!
Secondary outcome [3]
0
0
Duration of Objective Response (DOR) in Months for All Confirmed Responders
Query!
Assessment method [3]
0
0
DOR was defined as the time from the date of first confirmed response to the date of the first documented tumor progression (per RECIST v1.1), as determined by the investigator, or death due to any cause, whichever occurred first. DOR was evaluated only for confirmed responders (i.e. participants with confirmed CR or PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. Participants who neither progressed nor died were censored on the date of their last evaluable tumor assessment.
Query!
Timepoint [3]
0
0
From the date of first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurred first, up to approximately 94 months
Query!
Secondary outcome [4]
0
0
Progression Free Survival Rate (PFSR)
Query!
Assessment method [4]
0
0
PFSR was defined as the percentage of participants who did not experience disease progression or death from any cause at a given time point following randomization. Progression was assessed by investigators according to RECIST v1.1. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including on-treatment palliative radiation therapy (RT) of non-target bone lesions or CNS lesions) without a prior reported progression were to be censored at the last evaluable tumor assessment prior to or on initiation of the subsequent anti-cancer therapy.
Query!
Timepoint [4]
0
0
From randomization to specified timepoints, up to 84 months
Query!
Secondary outcome [5]
0
0
Progression-Free Survival (PFS) Time in Months for All Randomized Participants
Query!
Assessment method [5]
0
0
PFS was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator per RECIST v1.1 criteria, or death due to any cause. Participants underwent radiographic tumor assessments every 6 weeks (+/- 5 days) from week 9 (+/- 5 days) for the first year on treatment, then every 12 weeks after the first year on treatment until documented disease progression. The PFS curves were estimated using KM method. Two-sided 95% CI for median PFS were computed by Brookmeyer and Crowley method (using log-log transformation). Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including on-treatment palliative RT of non-target bone lesions or CNS lesions) without a prior reported progression were to be censored at the last evaluable tumor assessment prior to or on initiation of the subsequent anti-cancer therapy.
Query!
Timepoint [5]
0
0
From randomization up to the first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurred first, up to approximately 103 months
Query!
Secondary outcome [6]
0
0
Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12
Query!
Assessment method [6]
0
0
Disease-related symptom improvement rate by Week 12 was defined as the percentage of randomized participants who had a 10 point or greater decrease from baseline in average symptom burden index score at any time between randomization and Week 12. The participant portion of the Lung Cancer Symptom Scale (LCSS) consisted of 6 symptom-specific questions that addressed cough, dyspnea, fatigue, pain, hemoptysis, and anorexia, plus 3 summary items on symptom distress, interference with activity level, and global health-related Quality of Life (QoL). The scores range from 0 to 100, with 0 representing the best possible score and 100 being the worst possible score. The average symptom burden index score at each assessment was defined as the mean of the 6 symptom-specific questions of the LCSS. 95% CIs were computed using Clopper-Pearson Method.
Query!
Timepoint [6]
0
0
From randomization up to Week 12
Query!
Secondary outcome [7]
0
0
Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants
Query!
Assessment method [7]
0
0
OS was measured in months for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. OS was defined as the time between the date of randomization and the date of death from any cause. Participants were censored at the date they were last known to be alive. Median OS time was calculated using Kaplan-Meier (KM) method.
Query!
Timepoint [7]
0
0
From the date of randomization to the date of death from any cause, up to approximately 103 months
Query!
Secondary outcome [8]
0
0
Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants
Query!
Assessment method [8]
0
0
ORR was reported for all randomized participants grouped by their baseline PD-L1 expression level. ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CIs were computed using the Clopper and Pearson method.
Query!
Timepoint [8]
0
0
From the date of randomization up to the date of objectively documented progression, up to approximately 103 months
Query!
Secondary outcome [9]
0
0
Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants
Query!
Assessment method [9]
0
0
PFS time was measured for all randomized participants grouped by their baseline PD-L1 expression levels. PFS was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator per RECIST v1.1 criteria, or death due to any cause. The PFS curves were estimated using KM method. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who started subsequent anti-cancer therapy (including on-treatment palliative radiotherapy of non-target bone lesions or CNS lesions) without a prior reported progression were censored at the last evaluable tumor assessment prior to subsequent anti-cancer therapy.
Query!
Timepoint [9]
0
0
From the date of first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurred first, up to approximately 103 months
Query!
Eligibility
Key inclusion criteria
- Men and women =18 years of age
- Subjects with histologically or cytologically-documented squamous cell NSCLC who
present with Stage IIIB/IV disease or with recurrent or progressive disease following
multimodal therapy (radiation therapy, surgical resection or definitive chemoradiation
therapy for locally advanced disease)
- Disease recurrence or progression during/after one prior platinum doublet-based
chemotherapy regimen for advanced or metastatic disease
- Measurable disease by computed tomography (CT)/Magnetic resonance imaging (MRI) per
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status =1
- A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of
tumor sample (archival or recent) must be available for biomarker evaluation.
Specimens must be received by the central lab prior to randomization. Biopsy should be
excisional, incisional or core needle. Fine needle aspiration is insufficient
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects with untreated central nervous system (CNS) metastases are excluded. Subjects
are eligible if CNS metastases are treated and subjects are neurologically returned to
baseline for at least 2 weeks prior to enrollment. In addition, subjects must be
either off corticosteroids, or on a stable or decreasing dose of =10 mg daily
prednisone (or equivalent)
- Subjects with carcinomatous meningitis
- Subjects with active, known or suspected autoimmune disease. Subjects with type I
diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders
(such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or
conditions not expected to recur in the absence of an external trigger are permitted
to enroll
- Subjects with a condition requiring systemic treatment with either corticosteroids or
other immunosuppressive medications within 14 days of randomization
- Prior therapy with anti-Programmed death-1 (PD-1), anti-Programmed cell death ligand 1
(PD-L1), anti-Programmed cell death ligand 2 (PD-L2), anti-CD137, or anti-Cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) antibody (including ipilimumab or any other
antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
- Prior treatment on the first line study CA184104 first line NSCLC study
- Prior treatment with Docetaxel
- Subjects with interstitial lung disease that is symptomatic or may interfere with the
detection or management of suspected drug-related pulmonary toxicity
- Treatment with any investigational agent within 14 days of first administration of
study treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/10/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/08/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
272
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - 0073 - Wollongong
Query!
Recruitment hospital [2]
0
0
Local Institution - 0159 - Adelaide
Query!
Recruitment hospital [3]
0
0
Local Institution - 0140 - Elizabeth Vale
Query!
Recruitment hospital [4]
0
0
Local Institution - 0158 - Kurralta Park
Query!
Recruitment hospital [5]
0
0
Local Institution - 0085 - Clayton
Query!
Recruitment postcode(s) [1]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [4]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [5]
0
0
3168 - Clayton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Washington
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
West Virginia
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Buenos Aires
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Tucuman
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Cordoba
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Linz
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Salzburg
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Vienna
Query!
Country [24]
0
0
Austria
Query!
State/province [24]
0
0
Wels
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Manitoba
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Quebec
Query!
Country [27]
0
0
Chile
Query!
State/province [27]
0
0
Metropolitana
Query!
Country [28]
0
0
Chile
Query!
State/province [28]
0
0
Valparaiso
Query!
Country [29]
0
0
Chile
Query!
State/province [29]
0
0
Antofagasta
Query!
Country [30]
0
0
Chile
Query!
State/province [30]
0
0
Santiago
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Praha 8
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Avignon Cedes 9
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Caen
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Dijon
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
La Roche Sur Yon Cedex 9
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Lyon Cedex 08
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Marseille Cedex 20
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Pierre Benite
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Rennes Cedex 9
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Strasbourg
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Toulouse
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Bad Berka
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Essen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Gerlingen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Grosshansdorf
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Heidelberg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Koeln
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Krefeld
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Budapest
Query!
Country [50]
0
0
Ireland
Query!
State/province [50]
0
0
Dublin
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Bologna
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Meldola (fc)
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Milano
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Padova
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Perugia
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Ravenna
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Siena
Query!
Country [58]
0
0
Mexico
Query!
State/province [58]
0
0
Distrito Federal
Query!
Country [59]
0
0
Mexico
Query!
State/province [59]
0
0
Guanajuato
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Sonora
Query!
Country [61]
0
0
Netherlands
Query!
State/province [61]
0
0
Amsterdam
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Rotterdam
Query!
Country [63]
0
0
Norway
Query!
State/province [63]
0
0
Oslo
Query!
Country [64]
0
0
Peru
Query!
State/province [64]
0
0
Arequipa
Query!
Country [65]
0
0
Peru
Query!
State/province [65]
0
0
Lima
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Gdansk
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Krakow
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Olsztyn
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Szczecin
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Warszawa
Query!
Country [71]
0
0
Romania
Query!
State/province [71]
0
0
Bucuresti
Query!
Country [72]
0
0
Romania
Query!
State/province [72]
0
0
Cluj-Napoca
Query!
Country [73]
0
0
Romania
Query!
State/province [73]
0
0
Constanta
Query!
Country [74]
0
0
Romania
Query!
State/province [74]
0
0
Craiova
Query!
Country [75]
0
0
Romania
Query!
State/province [75]
0
0
Iasi
Query!
Country [76]
0
0
Romania
Query!
State/province [76]
0
0
Timisoara
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Moscow
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
St. Petersburg
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Vizcaya
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Barcelona
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Madrid
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Sevilla
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
East Yorkshire
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Hampshire
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Manchester
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Yorkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the study is to compare the overall survival of BMS-936558 as compared with
Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of
prior platinum-based chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01642004
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01642004
Download to PDF